Tirofiban for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis: A Systematic Review and Meta-Analysis
Cerebrovascular Diseases · 2023 · 52 (5) · 587-596
DOI: 10.1159/000527861 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Cerebrovascular Diseases, online erschienen am 29.12.2022. Verfasst von Heng Shi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hosp…. Hauptthemen laut MEDLINE: Stroke, Ischemic Stroke, Brain Ischemia, Endovascular Procedures. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Themen: Schlaganfall
Abstract (Originalsprache)
Introduction
Tirofiban has been used as a rescue when thrombectomy is not successful in endovascular therapy (EVT) for acute ischemic stroke (AIS), but the use of tirofiban after intravenous thrombolysis (IVT) is controversial. The purpose of this meta-analysis was to evaluate the safety and efficacy of tirofiban combined with IVT in AIS compared with not receiving tirofiban.
Methods
The PubMed and Embase databases were searched for all relevant studies published up to August 31, 2021. The safety endpoints included symptomatic intracranial hemorrhage (sICH), any intracranial hemorrhage (ICH), and mortality. The efficacy endpoint was the modified Rankin Scale (mRS) score at the 3-month follow-up.
Results
Seven articles (1,036 patients) were included. Of these, 444 patients received tirofiban, and 592 patients did not. Meta-analysis showed that tirofiban did not increase the risk of sICH (OR 0.98; 95% CI 0.50–1.93; p = 0.96), any ICH (OR 0.94; 95% CI 0.63–1.39; p = 0.75) or mortality (OR 0.67; 95% CI 0.39–1.15; p = 0.15) and tended to be associated with a favorable functional outcome (OR 1.33; 95% CI 0.99–1.78; p = 0.06) in patients with AIS. Subgroup analysis showed that bridging therapy combined with tirofiban could reduce mortality (OR 0.47; 95% CI 0.23–0.98; p = 0.04). Tirofiban significantly improved the favorable functional outcome in patients with IVT only (non-EVT) (OR 1.98; 95% CI 1.30–3.02; p = 0.002).
Conclusion
Intravenous tirofiban could be safe for patients with AIS undergoing IVT, regardless of receiving EVT. Intravenous tirofiban may reduce mortality rates for patients undergoing bridging therapy. It also could increase the likelihood of a favorable functional outcome, especially for patients receiving IVT only.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
- Third Clinical Medical College, Shanxi Medical University, Taiyuan, China.
Zitieren
APA
Shi, H., Hou, M. M., Ren, G., He, Z. F., Liu, X. L., Li, X. Y., & Sun, B. (2023). Tirofiban for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis: A Systematic Review and Meta-Analysis. Cerebrovascular Diseases, 52(5), 587-596. https://doi.org/10.1159/000527861
Vancouver
Shi H, Hou MM, Ren G, He ZF, Liu XL, Li XY, et al. Tirofiban for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis: A Systematic Review and Meta-Analysis. Cerebrovascular Diseases. 2023;52(5):587-596. doi:10.1159/000527861
BibTeX
@article{Shi2023,
author = {Shi, Heng and Hou, Miao-Miao and Ren, Gang and He, Ze-Fan and Liu, Xiao-Lei and Li, Xin-Yi and Sun, Bo},
title = {Tirofiban for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis: A Systematic Review and Meta-Analysis},
journal = {Cerebrovascular Diseases},
year = {2023},
volume = {52},
number = {5},
pages = {587--596},
doi = {10.1159/000527861}
}
EUVIMED